BR112016014115A2 - - Google Patents

Info

Publication number
BR112016014115A2
BR112016014115A2 BR112016014115A BR112016014115A BR112016014115A2 BR 112016014115 A2 BR112016014115 A2 BR 112016014115A2 BR 112016014115 A BR112016014115 A BR 112016014115A BR 112016014115 A BR112016014115 A BR 112016014115A BR 112016014115 A2 BR112016014115 A2 BR 112016014115A2
Authority
BR
Brazil
Application number
BR112016014115A
Other languages
Portuguese (pt)
Other versions
BR112016014115A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112016014115A2 publication Critical patent/BR112016014115A2/pt
Publication of BR112016014115A8 publication Critical patent/BR112016014115A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112016014115A 2013-12-19 2014-12-18 Derivados antibacterianos de 1h-indazol e 1hindol BR112016014115A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13198338 2013-12-19
PCT/EP2014/078384 WO2015091741A1 (en) 2013-12-19 2014-12-18 Antibacterial 1h-indazole and 1h-indole derivatives

Publications (2)

Publication Number Publication Date
BR112016014115A2 true BR112016014115A2 (enExample) 2017-08-08
BR112016014115A8 BR112016014115A8 (pt) 2017-12-26

Family

ID=49880464

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016014115A BR112016014115A8 (pt) 2013-12-19 2014-12-18 Derivados antibacterianos de 1h-indazol e 1hindol

Country Status (22)

Country Link
US (1) US9624206B2 (enExample)
EP (1) EP3083567B1 (enExample)
JP (1) JP6407288B2 (enExample)
KR (1) KR20160098503A (enExample)
CN (1) CN105829288B (enExample)
AR (1) AR100032A1 (enExample)
AU (1) AU2014368619B2 (enExample)
BR (1) BR112016014115A8 (enExample)
CA (1) CA2933604A1 (enExample)
CL (1) CL2016001524A1 (enExample)
EA (1) EA030730B1 (enExample)
ES (1) ES2666130T3 (enExample)
IL (1) IL246201A0 (enExample)
MA (1) MA39189A1 (enExample)
MX (1) MX360983B (enExample)
PH (1) PH12016501102A1 (enExample)
PL (1) PL3083567T3 (enExample)
SG (1) SG11201605014YA (enExample)
TR (1) TR201807881T4 (enExample)
TW (1) TW201609641A (enExample)
WO (1) WO2015091741A1 (enExample)
ZA (1) ZA201604968B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
WO2015173329A1 (en) 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
BR112017010474A2 (pt) 2014-11-19 2017-12-26 Actelion Pharmaceuticals Ltd derivados antibacterianos de benzotiazol
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
AR105839A1 (es) * 2015-08-28 2017-11-15 Actelion Pharmaceuticals Ltd Derivados antibacterianos pirrolidin-2-ona anulares
AR105848A1 (es) * 2015-08-31 2017-11-15 Actelion Pharmaceuticals Ltd Derivados heterocíclicos antibacterianos
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
AU2017267194A1 (en) * 2016-05-17 2019-01-17 Idorsia Pharmaceuticals Ltd 6-(BUTA-1,3-DIYN-1-YL)benzo[D]thiazole derivatives
WO2018216822A1 (en) 2017-05-25 2018-11-29 Taisho Pharmaceutical Co., Ltd. Novel imidazole derivatives
WO2019086452A1 (en) * 2017-10-31 2019-05-09 Idorsia Pharmaceuticals Ltd Antibacterial heteroaromatic compounds
CN113666860B (zh) * 2020-05-14 2024-03-15 鲁南制药集团股份有限公司 一种7-乙基色醇的制备方法
CN119014415B (zh) * 2024-08-19 2025-09-05 浙江大学 1-甲氧基吲哚在驱避和/或杀灭害虫中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
DE102004017930A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4931823B2 (ja) 2004-10-18 2012-05-16 アムジエン・インコーポレーテツド チアジアゾール化合物及び使用方法
PT1863818E (pt) 2005-03-23 2010-04-09 Hoffmann La Roche Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
WO2010135536A2 (en) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Methods of modulating uric acid levels
CA2774250C (en) * 2009-10-13 2013-12-17 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
JP5793766B2 (ja) 2009-12-16 2015-10-14 ファイザー・インク 抗菌剤として有用なn−結合型ヒドロキサム酸誘導体
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
EP2638006A1 (en) 2010-11-10 2013-09-18 Achaogen, Inc. Hydroxamic acid derivatives and their use in the treatment of bacterial infections
KR20120079015A (ko) 2011-01-03 2012-07-11 한미약품 주식회사 G 단백질-커플링된 수용체의 조절을 위한 신규한 비사이클릭 화합물
AP3336A (en) * 2011-03-07 2015-07-31 Pfizer Fluoro-pyridinone derivatives useful as antibacterial agents
WO2012137094A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
WO2012137099A1 (en) * 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
EP2847162A1 (en) 2012-05-09 2015-03-18 Achaogen, Inc. Antibacterial agents
WO2013170165A1 (en) 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
WO2015173329A1 (en) 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives

Also Published As

Publication number Publication date
TW201609641A (zh) 2016-03-16
IL246201A0 (en) 2016-08-02
US20170029411A1 (en) 2017-02-02
MX2016007991A (es) 2016-10-07
JP2017500336A (ja) 2017-01-05
EA030730B1 (ru) 2018-09-28
EP3083567B1 (en) 2018-03-07
CA2933604A1 (en) 2015-06-25
AU2014368619A1 (en) 2016-07-28
SG11201605014YA (en) 2016-07-28
ZA201604968B (en) 2018-11-28
CL2016001524A1 (es) 2017-01-27
EA201600475A1 (ru) 2016-11-30
MA39189A1 (fr) 2017-06-30
CN105829288B (zh) 2019-01-15
AR100032A1 (es) 2016-09-07
CN105829288A (zh) 2016-08-03
WO2015091741A1 (en) 2015-06-25
JP6407288B2 (ja) 2018-10-17
TR201807881T4 (tr) 2018-06-21
PH12016501102A1 (en) 2016-07-11
PL3083567T3 (pl) 2018-08-31
AU2014368619B2 (en) 2018-11-22
MX360983B (es) 2018-11-22
US9624206B2 (en) 2017-04-18
ES2666130T3 (es) 2018-05-03
BR112016014115A8 (pt) 2017-12-26
KR20160098503A (ko) 2016-08-18
EP3083567A1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
BR112016014154A2 (enExample)
AP2016009275A0 (enExample)
BR112016011061A2 (enExample)
BR112015007533A2 (enExample)
BR102016010778A2 (enExample)
BR112014017733A2 (enExample)
BR112014017739A2 (enExample)
BR112014018502A2 (enExample)
BR112014018516A2 (enExample)
BR112014017765A2 (enExample)
BR112014018480A2 (enExample)
BR112014017855A2 (enExample)
BR112016003217A2 (enExample)
BR112014020341A2 (enExample)
BR112014018468A2 (enExample)
BR112014017901A2 (enExample)
BR112014018483A2 (enExample)
BR112014017722A2 (enExample)
BR112014017653A2 (enExample)
BR112014018578A2 (enExample)
BR112014017601A2 (enExample)
BR112015015312A2 (enExample)
BR112014024039A2 (enExample)
BR112014018496A2 (enExample)
BR112014019048A2 (enExample)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements